Salarius Pharmaceuticals Inc (SLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has a cash flow conversion efficiency ratio of -0.388x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($4.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SLRX company net worth for the company's overall valuation and market capitalisation.
Salarius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Salarius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Salarius Pharmaceuticals Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Falmaco Nonwoven Industri PT Tbk
JK:FLMC
|
-0.007x |
|
In-Touch Survey Systems Ltd.
V:INX
|
-0.027x |
|
Opyl Ltd
AU:OPL
|
1.994x |
|
Destiny Media Technologies Inc
V:DSY
|
0.158x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
China Natural Resources Inc
NASDAQ:CHNR
|
-0.019x |
|
RKEC Projects Limited
NSE:RKEC
|
0.014x |
|
DomaCom Limited
AU:DCL
|
0.000x |
Annual Cash Flow Conversion Efficiency for Salarius Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Salarius Pharmaceuticals Inc from 2015 to 2024. View SLRX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -- |
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more